HANOVER, Germany--(BUSINESS WIRE)--Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced ...
Novo Nordisk is adding on to its cardiovascular drug pipeline with the acquisition of Cardior Pharmaceuticals, a genetic medicines developer whose lead program is in mid-stage clinical testing in ...
From heart failure with multiple comorbidities to rare disease scenarios, ICD-10 coding for complex conditions demands precision, updated knowledge, and strong provider collaboration. The FY 2026 ...